The Europe transgenic animal model market is set for robust growth, driven by surging biotechnology investments, demand for ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA.
Biomedical Engineering Is the Backbone of Modern Medical Advancement and the Biomedical Engineering Society (BMES) is ...
Morning Overview on MSN
A single gene-editing infusion cut severe swelling attacks by 87 percent in a trial
People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with ...
Genetic profiles and the gene editor CRISPR threaten to bring a new eugenics of gene selection, but even eugenicist Foster ...
The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results